NCT05536388 Drug Discovery for Parkinson's With Mutations in the GBA Gene
| NCT ID | NCT05536388 |
| Status | Recruiting |
| Phase | — |
| Sponsor | New York Stem Cell Foundation Research Institute |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-07-15 |
| Primary Completion | 2025-07-15 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Diagnosis of Parkinson's disease, Gaucher disease, or healthy control. * Must provide written informed consent unless physical limitations preclude signing. Exclusion Criteria: * For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection. * For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection. * For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.